Drugs / BF4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02907073 | Sep 2016 → Dec 2017 | endometrial cancer, plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BF4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02907073 ↗ |
| Modality | Diagnostic / imaging agent | “F-18 tetrafluoroborate (BF4) or (TFB) is being used as a PET (Positron Emission Tomography) imaging biomarker for expression of the human sodium/iodide symporter (hNIS) in tissues.” NCT02907073 ↗ |
| Route | Intravenous | “single i.v. bolus of \[18F\]BF4 for injection” NCT02907073 ↗ |